Neurocrine Biosciences Income Statement
NBIX / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 15 fiscal years. All figures from audited SEC 10-K filings.
Neurocrine Biosciences reported $2.9B in revenue and $479M in net income for FY2025. Revenue has grown at a 29.4% compound annual rate over the past 14 years.
Based on SEC 10-K filings.
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.9B | $2.4B | $1.9B | $1.5B | $1.1B | $1.0B | $788.1M | $451.2M | $0 | $15.0M | $19.8M | $0 | $2.9M | $53.1M | $77.4M |
| Cost of Revenue | $52.1M | $34.0M | $39.7M | $23.2M | $14.3M | $10.1M | - | $4.9M | $1.3M | $0 | $0 | - | - | - | - |
| SG&A Expense | $1.2B | $1.0B | $887.6M | $752.7M | $583.3M | $433.3M | $354.1M | $248.9M | $169.9M | $68.1M | $32.5M | $18.0M | $13.3M | $13.4M | $12.5M |
| R&D Expense | $1.0B | $731.1M | $565.0M | $463.8M | $328.1M | $275.0M | - | $160.5M | $121.8M | $94.3M | $81.5M | $46.4M | $39.2M | $37.2M | $31.0M |
| Operating Income | $619.1M | $570.5M | $250.9M | $249.0M | $102.5M | $163.0M | $72.3M | $36.8M | -$131.4M | -$147.4M | -$94.2M | -$64.4M | -$49.7M | $1.4M | $33.9M |
| Interest Expense | - | - | $4.6M | $7.1M | $25.8M | $32.8M | $32.0M | $30.5M | $19.5M | $0 | $0 | - | - | - | - |
| Income Tax | $226.8M | $144.7M | $82.4M | $59.4M | $11.8M | -$300.6M | $9.5M | $700.0K | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | $478.6M | $341.3M | $249.7M | $154.5M | $89.6M | $407.3M | $37.0M | $21.1M | -$142.5M | -$141.1M | -$88.9M | -$60.5M | -$46.1M | $5.0M | $37.6M |
| EPS (Basic) | $2.56 | $1.61 | $0.95 | $4.38 | $0.40 | $0.23 | -$1.62 | -$1.63 | -$1.05 | -$0.81 | -$0.69 | $0.08 | $0.68 | -$0.15 | -$1.30 |
| EPS (Diluted) | $2.47 | $1.56 | $0.92 | $4.16 | $0.39 | $0.22 | -$1.62 | -$1.63 | -$1.05 | -$0.81 | -$0.69 | $0.08 | $0.67 | -$0.15 | -$1.30 |
| Shares Outstanding | 99.4M | 98.7M | 96.5M | 94.9M | 93.5M | 92.3M | 90.8M | 88.8M | 86.9M | 86.3M | 76.5M | 67.4M | 66.4M | 55.3M | 54.9M |
| Operating Margin | 21.6% | 24.2% | 13.3% | 16.7% | 9.0% | 15.6% | 9.2% | 8.2% | - | -982.5% | -476.5% | - | -1701.9% | 2.7% | 43.8% |
| Profit Margin | 16.7% | 14.5% | 13.2% | 10.4% | 7.9% | 38.9% | 4.7% | 4.7% | - | -940.6% | -449.8% | - | -1579.0% | 9.5% | 48.5% |